Clinical Trial Update: Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin [Phase 2]

View source ↗

Summary

Phase 2 safety study evaluating pegylated interferon lambda in combination with one or two direct-acting antivirals plus ribavirin for hepatitis C has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Direct-acting antiviral agents (DAAs) (direct-acting antiviral agents)
• Pegylated Interferon Lambda (pegylated interferon lambda-1a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED